Monday, March 27, 2023
  • Login
198 Japan News
No Result
View All Result
  • HOME
  • BUSINESS NEWS
  • VIDEO NEWS
  • FEATURED NEWS
    • JAPAN US TRADE NEWS
    • JAPAN EU NEWS
    • JAPAN UK NEWS
    • JAPAN INDIA NEWS
    • JAPAN RUSSIA NEWS
    • JAPAN GULF NATIONS NEWS
    • JAPAN AFRICA NEWS
    • JAPAN EGYPT NEWS
    • JAPAN NIGERIA NEWS
    • JAPAN MEXICO NEWS
    • JAPAN BRAZIL NEWS
    • JAPAN THAILAND NEWS
    • JAPAN INDONESIA NEWS
  • CRYPTO
  • POLITICAL
  • TECHNOLOGY
  • JAPAN AGRICULTURE NEWS
    • JAPAN MANUFACTURE NEWS
    • JAPAN AGRICULTURE NEWS
    • JAPAN IMMIGRATION NEWS
    • JAPAN UNIVERSITY NEWS
    • JAPAN EDUCATION NEWS
    • JAPAN VENTURE CAPITAL NEWS
    • JAPAN JOINT VENTURE NEWS
    • JAPAN BUSINESS HELP
    • JAPAN PARTNESHIPS
  • ASK IKE LEMUWA
  • CONTACT
198 Japan News
  • HOME
  • BUSINESS NEWS
  • VIDEO NEWS
  • FEATURED NEWS
    • JAPAN US TRADE NEWS
    • JAPAN EU NEWS
    • JAPAN UK NEWS
    • JAPAN INDIA NEWS
    • JAPAN RUSSIA NEWS
    • JAPAN GULF NATIONS NEWS
    • JAPAN AFRICA NEWS
    • JAPAN EGYPT NEWS
    • JAPAN NIGERIA NEWS
    • JAPAN MEXICO NEWS
    • JAPAN BRAZIL NEWS
    • JAPAN THAILAND NEWS
    • JAPAN INDONESIA NEWS
  • CRYPTO
  • POLITICAL
  • TECHNOLOGY
  • JAPAN AGRICULTURE NEWS
    • JAPAN MANUFACTURE NEWS
    • JAPAN AGRICULTURE NEWS
    • JAPAN IMMIGRATION NEWS
    • JAPAN UNIVERSITY NEWS
    • JAPAN EDUCATION NEWS
    • JAPAN VENTURE CAPITAL NEWS
    • JAPAN JOINT VENTURE NEWS
    • JAPAN BUSINESS HELP
    • JAPAN PARTNESHIPS
  • ASK IKE LEMUWA
  • CONTACT
No Result
View All Result
198 Japan News
No Result
View All Result
Home JAPAN VENTURE CAPITAL NEWS

Made-in-China Medicine Testing the World Market

by 198 Japan News
December 29, 2021
in JAPAN VENTURE CAPITAL NEWS
Reading Time: 4 mins read
A A
0
Made-in-China Medicine Testing the World Market
Share on FacebookShare on Twitter

[ad_1]

You might also like

Modern American Animation

The Tony Robbins CANI! System For Success

The Best Independent Horror Movies of 2011

Many pharmaceutical companies in China are hoping to pass major international certifications, such as certifications from the WHO, EU and Australia. “It is likely that 20 pharmaceutical companies can obtain international certifications this year,” said Mr Yu Mingde, a vice-director of China Pharmaceutical Enterprises Management Association.

Temptation from the outside

2007 was another record year for China’s western medicine export value, up 56% to US$784 million. However, most medicines that went to big markets such as Japan, Korea and Australia were products from foreign companies in China, mainly in the form of export processing trades. Products made by domestic Chinese companies were exported to low end markets such as Nigeria and Pakistan. As Chinese pharmaceutical companies are still weak at proprietary R&D, most of their products are generic copycat drugs.

Yu revealed that “the big three markets of EU, US and Japan have different market systems to ours. For the same generic drug, profits from selling to the big three markets are 5-8 times of those in China.” A more pressing issue is that almost half pharmaceutical companies in China currently have idle capacities.

On one hand it is the high profit from international markets, on the other are the capacity surplus and vicious competition in the domestic market. It is not hard to see why the Chinese government has been emphasising medicine exports in its healthcare industry planning, and “going out” has also become a consensus in the Chinese pharmaceutical industry.

Access to the markets

The EU mandates that medicine access permits will only be granted to companies inside the EU jurisdiction. So if foreign companies want to sell medicines to the EU market, they have to establish local branches or find local partners. FDA in the US also has similar requirements.

Yu suggested that for Chinese medicine products to enter EU and US markets, Chinese companies may try arrangements such as local mergers and acquisitions, registration of local offices or seeking local partners, and local partnerships would probably be the easiest. It is understood that those companies whose products have passed the EU certification, such as Hisun Pharmaceutical, Wuxi Kaifu Pharmaceutical and Shanghai Tianping Pharmaceutical, have all chosen the partnership path.

Yu, who has 30 years’ pharmaceutical management experience, pointed out that regulations, processes and even social cultures in foreign markets are “very different” from China. He suggested that for Chinese companies that are “testing water”, in light of the reality of few foreign distribution channels, they can temporarily choose the OEM (original equipment manufacturing) or commissioned processing paths. Only when they become more sophisticated in this area, they may then go for mergers and acquisitions, local entity registration and brand building.

Zhejiang Reachall Pharmaceutical’s fast-track FDA approval in the US was a good example of smart leverage. In early 2007, a big American pharmaceutical distribution company approached Reachall, requiring it to produce ointment products for the North American market. After a series of inspection, research and negotiation, a long term cooperation agreement was signed between the parties. In the same year, an existing Reachall ointment product successfully obtained the FDA certification in US, and the first batch worth US$300,000 was shipped to the US in November.

Breaking the barriers

Since China’s entry into WTO in 2001, many European, American and Japanese pharmaceutical companies have been shifting their raw ingredient and intermediate product production processes to China. “Production outsourcing has taught Chinese companies a valuable lesson in terms of international practices, environmental awareness, quality control and patent protection, and this has greatly improved our competitiveness and international status.” Yu thought that behind the OEM orders and profits, medicine exports from China have to overcome the barriers of international standard integration and product quality breakthrough.

General Manager of Shenzhen Lijian Pharmaceutical, Mr Ouyang Qing, said that in terms of macro aspects, market access rules for medicines between the Chinese market and major overseas markets are similar. The differentiation lies in detailed administrative aspects, such as certification, risk assessment and variable products. Yu also stressed that apart from finished product certification, some overseas markets would require related certification of ingredients, in order to maintain the stability of product qualities.

As for how to find the sweet spots, there may be some examples to follow. According to Mr Ouyang, Shenzhen Lijian was previously in the business of exporting ingredient drugs, whose good quality had won a long term order for a German company. When Lijian decided to expand its valued-adding medicine production business, that German firm was at the same time thinking about shifting their OEM preparation production from France and Italy to lower-cost markets. “So our German partner had played a key role in Lijian’s winning of EU certification,” Mr Ouyang revealed.

And the key to Reachall’s quick FDA approval in US was the choice of products. Compound polymyxin B ointment is an OTC (over-the-counter) product in the US, and the FDA already had detailed requirements on the ointment’s quality, instruction and labelling. This ointment was popular in the US and had gained acceptance in terms of effectiveness and safety. On the other hand, Reachall was the first company in China to produce the generic version of the ointment, and the company had adopted FDA standards even when it was applying for certification in China. This no doubt helped its international entry.

To participate in global competition, the Chinese pharmaceutical industry has to make efforts in certification system integration, English communication skills, product selection and R&D. Company managers should also have long term planning, instead of being opportunistic.

“Don’t underestimate the demand for Chinese generic drugs from international markets, which have already shown great interests and tolerance to their Chinese counterparts,” Mr Ouyang suggested. Mr Yu also thought that there will be more and more Chinese pharmaceutical companies entering major overseas markets. But Yu reminded that there will be a new level of price and variety competition for winning multinational commissioned processing contracts in China. The biggest advantages for Chinese companies are their low costs and acceptable quality, but the profitability will gradually decline as more and more followers trying to take a piece of the cake.

[ad_2]

Source by Face Zhang

Tags: best franchises japanfranchises japanjapan corporate venture capitaljapan government venture capitaljapan mergers and acquisitionsjapan venture capitaljapan venture capital associationjapan venture capital marketjapanese franchisesMadeinChinaMarketMedicineTestingWorld
Share30Tweet19

Recommended For You

Modern American Animation

by 198 Japan News
March 3, 2022
0
Modern American Animation

This article describes the history of animation in the United States of America since the late 80's until the early twenty-first century. This period is often called the...

Read more

The Tony Robbins CANI! System For Success

by 198 Japan News
March 2, 2022
0
The Tony Robbins CANI! System For Success

Dr. W. Edward Deming is thought of as the person most responsible for bringing the "quality" movement to Japan. He believed that the best way to move Japan...

Read more

The Best Independent Horror Movies of 2011

by 198 Japan News
March 1, 2022
0
The Best Independent Horror Movies of 2011

In a previous post, I discussed the sad state of mainstream horror. Actually, that was my original intention. However, even writing about the pathetic retreads and overall lack...

Read more

PES 2013 – The Only Video Game For Footy Fans

by 198 Japan News
February 28, 2022
0
PES 2013 – The Only Video Game For Footy Fans

PES 2013 by Konami launches on PS3, XBOX 360, Wii and PC this autumn and will give FIFA 12 a run for its money this year if the...

Read more

Understanding a Forex Review and Benefiting

by 198 Japan News
February 27, 2022
0
Understanding a Forex Review and Benefiting

Before understanding a Forex review, you need to understand what Forex actually is? Forex is basically a market in which currencies are traded. It is known by many...

Read more
Next Post
Some Interesting McDonald’s Franchise History

Some Interesting McDonald's Franchise History

Overview of the Franchise Business in Myanmar

Overview of the Franchise Business in Myanmar

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Trending
  • Comments
  • Latest
FTX to Help Voyager Customers, CEO Says Firm Willing to Deploy ‘Hundreds of Millions’ to Help Crypto Industry – Bitcoin News

FTX to Help Voyager Customers, CEO Says Firm Willing to Deploy ‘Hundreds of Millions’ to Help Crypto Industry – Bitcoin News

July 24, 2022
California governor declares emergency over wildfire near Yosemite

California governor declares emergency over wildfire near Yosemite

July 24, 2022
China accuses Japan of interfering in its internal affairs on Taiwan question

China accuses Japan of interfering in its internal affairs on Taiwan question

July 24, 2022
Kyodo News Digest: July 24, 2022

Kyodo News Digest: July 24, 2022

July 24, 2022
With an eye on China, Seoul seeks to prevent tech leaks

With an eye on China, Seoul seeks to prevent tech leaks

July 23, 2022
Brands of Baseball Gloves

Brands of Baseball Gloves

July 23, 2022
198 Japan News

198 Japan News will provide the latest news update as the government facing a growing challenging in preventing Japan from breaking apart along ethnic and religious lines.

198massmedia Group. USA. 3821 Dominion Drive, Dumfries, USA. 22026.

Toll Free 1 888 642 8433.
Contact: info@198japannews.com

LATEST UPDATES

FTX to Help Voyager Customers, CEO Says Firm Willing to Deploy ‘Hundreds of Millions’ to Help Crypto Industry – Bitcoin News

California governor declares emergency over wildfire near Yosemite

China accuses Japan of interfering in its internal affairs on Taiwan question

Kyodo News Digest: July 24, 2022

With an eye on China, Seoul seeks to prevent tech leaks

Brands of Baseball Gloves

UPDATE 1-France tells Iran it’s disappointed at lack of progress over nuclear talks

Neymar declares wish to stay at Paris Saint Germain

RECOMMENDED

No Content Available

Copyright © 2021 198 Japan News.

No Result
View All Result
  • Browse the latest updates from Japan
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

Copyright © 2021 198 Japan News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In